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Abstract
Bone marrow mesenchymal stromal cells (BM MSCs) represent a heterogeneous population of progenitors with potential
for generation of skeletal tissues. However the identity of BM MSC subpopulations is poorly defined mainly due to the
absence of specific markers allowing in situ localization of those cells and isolation of pure cell types. Here, we aimed at
characterization of surface markers in mouse BM MSCs and in their subsets with distinct differentiation potential. Using
conditionally immortalized BM MSCs we performed a screening with 176 antibodies and high-throughput flow cytometry,
and found 33 markers expressed in MSCs, and among them 3 were novel for MSCs and 13 have not been reported for MSCs
from mice. Furthermore, we obtained clonally derived MSC subpopulations and identified bipotential progenitors capable
for osteo- and adipogenic differentiation, as well as monopotential osteogenic and adipogenic clones, and thus confirmed
heterogeneity of MSCs. We found that expression of CD200 was characteristic for the clones with osteogenic potential,
whereas SSEA4 marked adipogenic progenitors lacking osteogenic capacity, and CD140a was expressed in adipogenic cells
independently of their efficiency for osteogenesis. We confirmed our observations in cell sorting experiments and further
investigated the expression of those markers during the course of differentiation. Thus, our findings provide to our
knowledge the most comprehensive characterization of surface antigens expression in mouse BM MSCs to date, and
suggest CD200, SSEA4 and CD140a as markers differentially expressed in distinct types of MSC progenitors.
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Introduction
Bone marrow stroma is a complex tissue consisting of many cell
types, which provide a microenvironment for haematopoiesis and
also contribute to the maintenance and regeneration of skeletal
tissues [1,2,3]. Perturbed function of stromal tissue in humans can
cause severe defects of skeletal system [4,5,6,7] or dysregulation of
haematopoiesis resulting in myelodysplasia and acute myeloid
leukemia [8,9]. On the other hand, capacity of stromal cells to
differentiate into osteoblasts and chondrocytes makes them an
important source for tissue engineering [10,11] and provided
success of treatment of patients with osteogenesis imperfecta [12],
and immunosuppressive properties have already brought them to
application in clinic to suppress graft-versus-host disease, GVHD
[13].
These facts underline a need for developing protocols for cell
replacement therapies, improving methods for stromal cell
isolation and also understanding a physiological role of cellular
components of bone marrow stroma.
Life-term replacement of stromal cells is supported by self-
renewing mesenchymal stem cells that possess several character-
istics including (1) clonogenicity in vitro, (2) multilineage differen-
tiation into the cells of mesenchymal origin, including osteogenic,
adipogenic and chondrogenic, and (3) ability to establish
haematopoiesis upon transplantation. However, current methods
of stromal cell isolation do not allow derivation of a pure
population of stem cells and therefore cultured bone marrow
stromal cells represent a mixture of their descendants, including
progenitors of different types, hereafter referred as mesenchymal
stromal cells (MSCs).
The isolation of pure cell types from bone marrow stroma and
their in vivo localization is hindered by the lack of known specific
surface markers for those cells. To date only a combination of
markers can define stem/stromal cells from bone marrow, and
none of them is unique. In humans, CD146 (MCAM) has been
proposed as a marker for osteogenic cells in stromal tissue capable
of establishment of haematopoietic microenvironment, which
together meet the definition of mesenchymal stem cell [14]. In
mice, a population of CD45neg TER119neg PDGFRapos Sca1pos
sorted cells (PaS) contained multipotent cells that could engraft
into MSC compartment after transplantation [15]. However, the
clonally derived lines of CD146pos or PaS MSCs exhibited
differences in differentiation potentials and transplantability,
which may indicate heterogeneity within those cell populations.
Several approaches have been developed for in situ localization
and lineage tracing of mesenchymal stem cells using mouse
transgenic models. It has been shown that in the bone marrow
perivascular cells expressing nestin-GFP reporter constitute the
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haematopoietic niche and contribute to skeletal tissues in lineage-
tracing experiments [16]. Recently, Mx1-Cre has been proposed
as a marker capable to label the cells that produce osteoblastic
lineage life-long in the mice [17]. It was also noted, that Mx1-
labelled cells only partially overlap with nestin positive population
showing that cellular composition within those pools, each of
which display mesenchymal stem cell properties, can be still
complex.
Expression of surface antigens in cultured human bone marrow
MSCs has been intensively studied by staining with existing
antibodies [18,19,20], using proteomic approaches [21,22,23,24]
and by analysis of their transcriptome [25,26]. In these works it
has been noted that the levels of expression of some surface
markers correlates with differentiation capacity of MSC. For
example, CD106 and MSCA-1 mainly mark the adipogenic
progenitors in cultured human MSCs, whereas ITGA11 is
expressed on the cells with osteogenic capacity [20,26,27].
Mouse bone marrow MSCs are particularly difficult to
characterize due to the low proliferative activity of the cells in vitro
and substantial contamination of cultures by the cells of
haematopoietic origin [28,29]. At the same time, experience from
other stem/progenitor cell types, such as haematopoietic or
embryonic, shows that expression of surface epitopes in mouse
cells does not always mirror their human counterpart [30,31].
Since mouse model provides an important platform to study
fundamental properties of bone marrow MSCs and is often used
for preclinical studies, we were encouraged to perform an
extensive study of surface markers in murine MSCs. Previously
our group generated a transgenic mouse with inducible expression
of SV40 Large T-antigen for conditional immortalization of
somatic cells including bone marrow MSCs [32]. Importantly
those cells did not change the immunophenotype after long-term
culturing, which makes them useful for studies of surface markers.
In this report, we characterized the expression of surface markers
in conditionally immortalized bone marrow MSC lines using a
large panel of antibodies. As a step further we characterized
clonally derived MSC progenitors with distinct differentiation
potential aiming to find specific markers for MSC subsets, which
we could confirm in cell sorting experiments.
Materials and Methods
Cell Isolation and Culture
Bone marrow MSCs were derived from transgenic mice with a
modified tetracycline-inducible SV40 Large T-antigen generated
previously by our group [32]. All protocols related to animal
experiments were performed accordingly to the German Animal
Welfare Legislation, and the Animal Welfare Officer(s) appointed
for the facility oversaw them. For cell isolation bone marrow was
flushed from tibia and femurs and plated to cell culture dishes in
growth medium DMEM containing 1 g/L D-glucose (Gibco, Life
Technologies) supplemented with 10% fetal calf serum (FCS,
PAA). After reaching confluency the cells were passaged by
diluting 1:2 without or with adding 1027 M Dexamethasone (Dex)
and 1 mg/ml Doxycycline (Dox, both from Sigma) to induce the
expression of T-antigen. Conditionally immortalized BM MSCs
were routinely cultured in the growth medium in the presence of
Dex/Dox and passaged every 3–5 days with dilution 1:5–1:10.
Cellular cloning was performed by manual dilutions by plating the
cells at 1 or 3 cells per well of 96-well plate. After 2 weeks the
plates were checked for clones rising from single cells, which were
further collected and passaged in 96-well plates using multi-
channel pipette. The clones were screened for their potential to
differentiate into osteogenic and adipogenic lineages in 96-well
plates, at least in triplicates. The clones with distinct differentiation
potentials were selected and further expanded.
Differentiation of BM MSCs
For differentiation assays, BM MSCs were deinduced by Dex/
Dox withdrawal for 3 days to stop cell proliferation, and then
differentiation conditions were applied to the cells. Osteogenic
differentiation was performed in the growth medium by adding
1028 M Dex, 300 mM ascorbic acid and 10 mM b-glycerophos-
phate. After 2 weeks the cells were fixed with ice-cold methanol for
10 min, stained with 2% Alizarin Red at pH 4.3 for 10 min and
dried. For quantification of the efficiency of differentiation the dye
was extracted from the stained samples using 4 M guanidine
chloride solution at 37uC overnight, and the optical density of
extract was measured at 490 nm. For adipogenic differentiation
1027 M Dex, 5 mg/ml insulin and 5 mg/ml Troglitazone were
added to the growth medium for 7 days. The cells were fixed with
4% formaldehyde in phosphate buffered saline (PBS) for 30 min at
room temperature and stained with Oil Red (0.3% solution in
isopropanol mixed 3:2 with water and filtered) for 5 min. To
estimate the efficiency of differentiation the rate of adipocytes was
counted using phase contrast microscope at least in three fields of
view. Chondrogenic differentiation was done in pellet culture
prepared from 106 cells in the medium containing DMEM with
4.5 g/L D-glucose, 1% FCS, 10 ng/ml TGF-b1 (Peprotech),
1027 M Dex, 6.25 mg/ml apo-transferrin, 6.25 mg/ml insulin and
50 mg/ml ascorbate-2-phosphate. After 3 weeks the pellets were
fixed in 4% formaldehyde in PBS for 10 min at room temperature,
then paraffin embedded and sectioned. The sections were re-
hydrated and stained with anti-aggrecan antibody (1:100,
Chemicon) for 1 hour at 37uC. The staining was visualized using
Vectastain ABC kit (Vector Labs) according to manufacturer
recommendations. All chemicals were purchased from Sigma,
unless otherwise stated.
Cell Surface Marker Screening
BM MSCs were characterized using BD Lyoplate Mouse Cell
Surface Marker Screening Panel (BD Biosciences, cat. 562208),
which contains 176 monoclonal antibodies and correspondent
isotype controls. The staining was done according to manufacturer
protocol with minor modifications. Conditionally immortalized
MSCs were expanded, and then Dex and Dox were omitted from
the growth medium for 3 days to deinduce T-antigen expression.
The cells were dissociated using PBS with 10 mM EDTA, washed,
filtered through 40 mm nylon mesh and distributed into U-bottom
96-well plates in the concentration 2.5–56105 cells per well in
PBS+2%FCS. The incubation with primary antibodies was done
in 50 ml (0.5 mg antibodies per 106 cells) for 30 min at +4uC,
followed by two times washing. After that the cells were incubated
with the biotinylated secondary antibodies (goat anti-rat 1:400,
goat anti-armenian hamster 1:800, goat anti-syrian hamster 1:400
or goat anti-mouse 1:400) for 30 min at +4uC. After the wash,
incubation with Alexa647-Streptavidin conjugate (1:4000) was
done for 30 min at +4uC. The cells were fixed with 2%
formaldehyde solution in PBS. The measurement was done using
flow cytometer BD LSRII with High-Troughput Screening 96-
well plate loader (HTS FACS, BD).
FACS Sorting
A similar staining protocol was applied for other flow cytometry
measurements and cell sorting; the antibodies used for this work
were rat anti-mouse CD200 (BD Pharmingen, 552512), rat anti-
mouse CD140a (BD Pharmingen, 558774) and mouse anti-mouse
SSEA4 (BD Pharmingen, 560073). FACS sorting was done using
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BD FACS AriaII (BD Biosciences). The data was analyzed using
BD FACS Diva and FlowJo (TreeStar) software.
qRT-PCR
Total RNA was isolated by phenol-chloroform extraction from
cell lysate prepared with TRI Reagent (Sigma). 1 mg of RNA was
used for DNase I treatment (Invitrogen) and cDNA synthesis
(Affinity Script Multiple Temperature cDNA Synthesis kit,
Agilent). Quantitative PCR was done with GoTaq qPCR Master
Mix (Promega) in 384-well plates using LightCycler480 (Roche).
The primers were following (59-39): Rpl19 FWD CTGATCAAG
GATGGGCTGAT, Rpl19 REV GGCAGTACCCTTCCTCT
TCC, PPARg1 FWD TGAAAGAAGCGGTGAACCACTG, PP
ARg1 REV TGGCATCTCTGTGTCAACCATG, CD200 FWD
CTGGAAACGTCACCGAAATC, CD200 REV TCCCTCC
TGCTTTTCTTTCA, Sp7 FWD TCCTCGGTTCTCTCCAT
CTG, Sp7 REV GGACTGGAGCCATAGTGAGC, Alpl FWD
GGGACGAATCTCAGGGTACA, Alpl REV TTCAAGGT
CTCTTGGGCTTG, Plin4 FWD GCCACATACAGCACAAC
CAG, Plin4 REV CTACCAACAGCCTCCACCAT, CD140a
FWD ACAGAGACTGAGCGCTGACA, CD140a REV CGA
TGGTCTCGTCCTCTCTC, AP2 FWD GATGGTGACAA
GCTGGTGGT, AP2 REV AATTTCCATCCAGGCCTCTT.
Western Blot
Whole cell protein extracts were prepared by freezing and
thawing of cells in the extraction buffer (20 mM Hepes Ph 8.0,
350 mM NaCl, 10% glycerol, 0.1% Tween-20, 2 mM EDTA,
1 mM DTT, 1 mM PMSF, 1% Protease Inhibitor Coctail, all
Sigma). 20 mg of proteins were resolved in PAGE gel and
transferred to nitrocellulose membrane using semi-dry blotting.
Blocking was done overnight in 5% milk in PBS with 0.1%
Tween-20 at +4uC. The membranes were incubated with primary
antibodies (mouse monoclonal against T-antigen, 1:1000, Santa
Cruz) for 1 hour at room temperature, washed and incubated with
secondary horseradish peroxidase-conjugated goat anti-mouse
antibodies (1:2000, Pierce Thermo Scientific) in the same
conditions. Detection was performed using SuperSignal West
Femto Substrate kit (Pierce Thermo Scientific).
Results
Characterization of Conditionally Immortalized Mouse
Bone Marrow MSCs
To establish expandable MSCs we isolated cells from the bone
marrow of transgenic mice carrying a modified system for
tetracycline-regulated expression of SV40 Large T-antigen, which
has been reported previously by our group [32,33]. The expression
of Large T was induced in primary MSCs in the presence of two
ligands, Dexamethasone and Doxycycline (Dex and Dox),
resulting in rapid cell proliferation (Fig. 1A, B). The conditionally
immortalized cells could be passaged practically indefinitely,
whereas uninduced cells had limited growth potential and
exhibited signs of senescence after 1–3 passages [32]. After
removing Dex/Dox from the medium, T-antigen was not
expressed anymore (Fig. 1C), and consequently the cells stopped
dividing, showing that immortalization was reversible. Deinduced
cells could be differentiated into osteogenic, adipogenic and
chondrogenic lineages (Fig. 1D) by applying culture conditions
described for MSCs, indicating that immortalization did not affect
the differentiation potential of MSCs.
To characterize the expression of surface markers in mouse
bone marrow MSCs we used conditionally immortalized lines
from two individual mice (#6472 and #6652) for screening using
an antibody panel BD Lyoplate and high-throughput flow
cytometry. The immortalization was deinduced by Dex/Dox
withdrawal for 3 days before the experiment to avoid influence of
T-antigen expression to the cell properties. The Mouse Cell
Surface Marker Screening Panel contains 176 specific monoclonal
antibodies and corresponding isotype controls. Amongst the
markers present in the panel we identified 13 antigens that were
homogeneously and highly expressed on the surface of bone
marrow MSCs, with more than 85% of cells in the positive gate
(Table 1, Fig. 1E). These included CD9 (Tetraspanin 29), CD24
(Heat Stable Antigen), CD29 (Integrin beta-1), CD44 (Hyaluronic
acid receptor), CD47 (Integrin-associated protein), CD49e (Inte-
grin alpha-5), CD81 (Tetraspanin 28), CD98 (Slc3a2), CD106
(Vcam1), CD138 (Syndecan-1), CD147 (Basigin), Cr1l (comple-
ment component 3b/4b receptor 1-like), Sca1 (Stem Cell Antigen
1).
We detected 20 markers, which were moderately expressed or
showed heterogeneous staining within MSC population with more
than 5% of cells in the positive gate (Table 1, Fig. S1).
All the other antibodies used for the screening did not show a
positive staining (143 markers). Notably, we did not detect
expression of haematopoietic markers, such as CD11b, CD19,
CD34, CD45, corresponding to characteristics of MSCs and
confirming the absence of contamination with the cells of blood
lineages. The immunophenotype of bone marrow MSCs was
essentially reproduced in two lines that we used for the screening.
The complete results of the screening are shown in (Fig. S1, S2).
Characterization of Bone Marrow MSC Subpopulations
We aimed to dissect a population of MSCs at the single-cell level
and characterize progenitors committed to different lineages
focusing on the osteogenic and adipogenic properties. For this
purpose we performed cellular cloning of conditionally immortal-
ized MSCs and established clonally derived subpopulations from
MSC lines derived from two individual mice (#6472 and #6652).
The clones were screened for their potential to differentiate into
osteocytes and adipocytes (Fig. 2A). The differentiation assays
were done in at least 3 independent experiments and only
completely reproducible results were considered for the analysis.
We identified bipotential clones capable for both types of
differentiation (OA), as well as monopotential progenitors for
osteo- and adipogenic lineages, O and A, respectively (Fig. 2B, C).
To characterize the expression of surface markers in different
types of MSC progenitors we performed a screening by staining
with Lyoplate Antibody Panel and flow cytometry, considering
only those antigens that we found to be positive or moderately
positive/heterogeneous in the initial MSC lines (33 antibodies).
For each MSC subsets (OA, O, A) we chose 4 representative
clones, two originating from each of two mice (in total 12 clones).
All clones were positive for the markers, which were highly and
uniformly expressed in the original MSC lines, listed in Table 1.
Of a particular interest was to analyze the expression of markers
that showed heterogeneous staining in the parental lines. Most of
those antigens exhibited similar intensity of staining to the MSC
lines and amongst the clones. But we also detected differences in
the expression of three antigens between MSC subsets, and among
them CD200 (OX-2), SSEA4 (stage-specific embryonic antigen 4)
and CD140a (platelet-derived growth factor receptor alpha),
(Fig. 2D, E). CD200 was expressed higher in all clones with
osteogenic potential (OA and O) than in the A monopotential
clones, 3.3- and 2.7-fold (P,0.05), respectively, by comparing the
Mean Fluorescence Intensity (MFI). Conversely, SSEA4 was
represented more in the A clones with MFI of 1.9- and 2.2-fold
higher relatively to OA and O clones (P,0.01). A similar pattern
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Figure 1. Characterization of conditionally immortalized mouse bone marrowMSCs. (A) An improved tet-inducible system for conditional
expression of Large T-antigen. In the presence of Dex/Dox irtTA-GBD* fusion protein can be translocated to the nucleus and activate transcription of
Large T. (B) MSCs were isolated from bone marrow of transgenic mice and expanded in the immortalization conditions (Phase Contrast, 206). (C)
Western blot showing induction of T-antigen in primary MSCs (‘‘2‘‘ cells before induction, ‘‘+DD’’ induced cells, ‘‘2DD’’ cells deinduced for 3 days). (D)
Conditionally immortalized MSCs maintained differentiation potential in vitro into osteo-, adipo- and chondrogenic lineages. (E) Flow cytometry
results for the markers highly expressed in MSCs, as shown by the staining with BD Lyoplate Antibody Screening Panel. Abbreviations: Dex –
Dexamethasone, Dox – Doxycycline, irtTA – improved reverse tetracycline transactivator, GBD* - mutated glucocorticoid-binding domain, TAg –
Large T-antigen, CAGGs and PGK – constitutively active promoters, tet-tk – tetracycline operator and minimal promoter, IRES – internal ribosome
binding site, Puro and Hygro – puromycin and hygromycin resistance genes.
doi:10.1371/journal.pone.0051221.g001
Table 1. Immunophenotype of conditionally immortalized mouse BM MSCs.
Marker Alternate name % of positive Ref
Highly expressed
CD9 Tspan29, Tetraspanin 29 99.1 [25]
CD24 HSA, Heat Stable Antigen 98.6 [18]*
CD29 Itgb1, Integrin beta-1 90.7 [25], [18,50]*
CD44 Hyaluronate receptor 99.0 [25,51], [18,50]*
CD47 Itgp, Integrin-associated protein 97.6 [21,25]
CD49e Itga5, Integrin alpha-5, Fibronectin receptor 97.5 [25,51], [18]*
CD81 Tspan28, Tetraspanin 28 97.8 [25,51], [18]*
CD98 Slc3a2, Solute Carrier family 3 member 2 95.3 [21]
CD106 Vcam1, Vascular Cell Adhesion Molecule 1 92.1 [25], [28]*
CD138 Sdc1, Syndecan-1 94.8 N
CD147 Bsg, Basigin 94.0 [51]
Cr1l Complement component (3b/4b) receptor 1-like, Crry, p65 93.8 N
Sca1 Ly6a, Stem Cell Antigen-1 85.3 [18,50,52]*, +/2 [28]*
Moderately or heterogeneously expressed
CD13 Anpep, Aminopeptidase N 6.4 [25]
CD51 Itgav, Integrin alpha-v, Vitronectin receptor 52.8 [21,25], [18]*
CD61 Itgb3, Integrin beta-3 30.7 [25], [18]*
CD71 Tfrc, Transferrin receptor 55.1 [21], [18]*
CD73 Nt5e, Ecto-59-nucleotidase 28.1 [25]
CD80 T-lymphocyte activation antigen CD80 20.1 [18]*
CD95 Fas, TNF receptor superfamily member 6 11.8 [18]*
CD107b Lamp2, Lysosomal-Associated Membrane Protein 2 9.7 [21]
CD119 Ifngr1, Interferon Gamma Receptor Alpha 60.1 [53]
CD120a Tnfrsf1a, TNF Receptor superfamily member 1a 11.2 [54]
CD120b Tnfrsf1b, TNF Receptor superfamily member 1b 38.9 [25], [18]*
CD140a Pdgfra, PDGF Receptor alpha 14.5 [25,51], [18,52]*
CD172a Sirpa, Signal-Regulatory Protein alpha 7.8 [55]
CD200 OX-2 16.0 [25]
IFNgR1b Interferon gamma receptor 1, beta chain 8.5 [53]
Sdc4 Syndecan-4 58.5 N
Ly-51 Enpep, Glutamyl Aminopeptidase, CD249 34.6 [56]
H-2Kb H-2Kb MHC class I alloantigen 60.5 [50]*
H-2Db H-2Db MHC class I alloantigen 67.0 N
SSEA-4 Stage Specific Embryonic Antigen 4 11.2 [25], [46]*
*reported for mouse BM MSCs.
+/2reported as inconsistent level of expression between MSC preparations.
N-not reported for expression in MSCs before.
doi:10.1371/journal.pone.0051221.t001
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was found for CD140a, which was 2.4- and 2.2-fold higher
expressed in the A clones compared to OA and O, respectively,
although with lower significance (P,0.07).
It has to be noted that we detected the presence of all three
antigens in most of the analyzed clones, but the levels of expression
correlated with the differentiation properties of the cells (Fig. 2D).
Therefore, we proposed CD200, SSEA4 and CD140a as
differentially expressed between bone marrow MSC progenitors
committed to different lineages.
Comparison of Bone Marrow MSC Subsets Sorted for
CD200, SSEA4 and CD140a Expression
To validate differential expression of CD200, SSEA4 and
CD140a in distinct types of bone marrow MSC progenitors we
decided to separate MSC subsets with high and low levels of those
markers and test the resulted subpopulations for differentiation
potential. We stained two conditionally immortalized mouse bone
marrow MSC lines (#6472 and #6652) individually with the
antibodies for CD200, SSEA4 and CD140a, and sorted distinct
subpopulations with high and low expression of those markers by
FACS (Fig. 3A). The obtained subpopulations were checked for
the level of CD200 and PDGFRa mRNAs by qRT-PCR
immediately after sorting (Fig. 3B), SSEA4 has no correspondent
transcript, as it is an oligosaccharide. As expected, CD200high
sorted population expressed 7.1-fold higher level of CD200 as
mRNA, and CD140ahigh cells had 5.9-fold more of PDGFRa,
confirming the efficiency of the sorting. We also noted that
SSEA4high cells expressed 1.5 times higher CD140a and 1.5 times
lower CD200 than SSEA4low subset. Additionally, we tested the
levels of lineage-specific markers in the cells, characteristic for
osteogenic (Sp7 and Alpl) and adipogenic commitment (PPARg,
AP2, Plin4). We confirmed higher expression of osteogenic
markers by CD200high compared to CD200low subpopulations
(2.8-fold for Sp7 and 1.5-fold for Alpl), whereas PPARg, AP2 and
Plin4 were present at similar levels. On the opposite, the
SSEA4high MSC subpopulation had upregulated adipogenic marks
(4.2- to 5.5-fold) and downregulated osteogenic (2.8-fold for Sp7
and 1.3-fold for Alpl) relatively to SSEA4low. CD140ahigh cells
expressed remarkably higher levels of adipogenic markers than
CD140alow (13.4-fold for PPARg, 102-fold for AP2 and 4-fold for
Plin4), whereas osteogenic markers Sp7 and Alpl were not
consistently changed.
The sorted subpopulations were expanded in the immortaliza-
tion conditions and further tested for their differentiation capacity
(Fig. 3C, D). We found that CD200high MSCs had higher
osteogenic (P,1025) and lower adipogenic potential (P,1022)
compared to CD200low subset. The cells sorted for high SSEA4
expression exhibited more efficient adipogenic (P,1025) and less
efficient osteogenic differentiation (P,1022) than SSEA4low cells.
CD140ahigh subpopulation was more adipogenic relatively to
CD140alow (P,361025), whereas osteogenic properties varied
between subsets isolated from different mice and did not show
consistent difference. Generally, the differentiation capacity of the
expanded sorted subpopulations was in concordance to the
expression of lineage-specific markers on mRNA level, defined
by qPCR immediately after sorting. These results were reproduced
in the experiments using two independent mouse MSC lines.
We compared the levels of all three markers CD200, SSEA4
and CD140a by FACS in the high/low sorted subpopulations after
expansion for at least 5 passages after sorting (Fig. 3E, Fig. S3).
CD200high cells expressed 2.2-fold higher level of CD200 (P,0.01)
and 1.4-fold lower of SSEA4 (P,0.02) compared to CD200low
population. Conversely, SSEA4high cells showed 1.9-fold higher
expression of SSEA4 and 1.6-fold lower of CD200 relatively to
SSEA4low. The level of CD140a was not significantly different
between CD200high/CD200low and SSEA4high/SSEA4low popu-
lations. Corresponding to that, CD140ahigh cells did not exhibit
major differences in expression of CD200 and SSEA4 markers to
CD140alow, and at the same time had 4.5-fold upregulated
CD140a.
Summarizing those results, a high level of CD200 marks MSC
progenitors with elevated osteogenic potential, whereas SSEA4 is
expressed in the adipogenic cells, and high expression of those
markers is mutually exclusive. These results were confirmed by the
staining with combination of these antibodies (Fig. S4). CD140a is
present at high level in adipogenic cells, but its expression does not
exclude the osteogenic properties in this subpopulation.
Expression of Markers during Differentiation of Bone
Marrow MSCs
In order to check whether the markers differentially expressed
in the MSC progenitors with distinct lineage commitment, are
associated with differentiation process, we tested expression of
CD200, SSEA4 and CD140a during the time course of osteogenic
and adipogenic induction.
We performed osteogenic differentiation with two clones of the
OA type and two O clones, and adipogenic differentiation with the
same two OA and two A clones (Fig. 4A). The expression of
markers was checked in undifferentiated cells (day 0), during the
time course of differentiation (days 3 and 5 for adipogenesis, days
3, 5 and 10 for osteogenesis, for the latter only days 3 and 10 are
shown), (Fig. 4B, C). Flow cytometry results showed that CD200
was upregulated during osteogenic induction of OA and O clones,
but stayed on the similar level during adipogenesis. SSEA4 was
gradually downregulated in all clones in differentiation conditions.
CD140a did not change during osteogenic differentiation. During
adipogenic treatment of the OA clones CD140a peaked on the day
3 and then dropped, but it was downregulated from early stages of
adipogenic induction of the A clones, which had had a high level
of CD140a before applying differentiation conditions.
Discussion
Functional studies of specific cell types are inevitably based on
the ability to visualize the cells in the tissue context or to isolate
pure cell populations and estimate their homogeneity. Isolation of
HSCs expressing the set of well-established surface antigens
[34,35] and localizing intestinal stem cells using Lgr5 reporter [36]
provided extraordinary examples of breaking through in these
Figure 2. Characterization of clonally derived bone marrow MSC progenitors. (A) Cellular cloning of conditionally immortalized MSCs was
performed by limiting dilutions, and the resulted single-cell derived subpopulations were cultured in 96-well plates and screened for the potential for
osteogenic and adipogenic differentiation. (B) Differentiation assay revealed the bipotential clones capable of osteo- and adipogenesis ‘‘OA’’, and
monopotential osteo- and adipogenic clones, ‘‘O’’ and ‘‘A’’. (C) Summary of screening of two independent MSC lines. (D) Flow cytometry results of
staining of clonally derived MSC progenitors with OA, O and A potential, for the differentially expressed markers CD200, SSEA4 and CD140a. The
percent of cells in the positive gate is indicated on the histogram. (E) Comparison of levels of differentially expressed markers CD200, SSEA4 and
CD140a shown by Mean Fluorescence Intensity of flow cytometry measurement, between OA, O and A progenitors. 4 clones of each type were used
for experiment, statistical significance is indicated.
doi:10.1371/journal.pone.0051221.g002
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fields of research. Unfortunately, those stem cell types are
exceptions among many others existing in mammalian body.
Despite accumulating knowledge on the location and functions of
bone marrow mesenchymal stem cells [14,16,17], a concise view
on their identity is still missing and furthermore the hierarchy of
their descendants is not defined.
In vitro culture systems represent a model to study cell properties
and can provide sufficient cell numbers for biochemical charac-
terization, although caution should be taken because of possibly
introduced artifacts. It has been previously noted that cultured
human BM MSC are changing their differentiation properties and
expression of markers during passaging [27,37,38], which hampers
the studies of their properties and makes characterization of BM
MSC subtypes complicated. Moreover, mouse BM MSCs are
difficult to expand [28,39] and therefore are not well described.
We applied conditional immortalization for BM MSC expansion
by isolating the cells from transgenic mice carrying inducible SV40
Large T-antigen [32,33]. This system enables expression of Large
T in the presence of two compounds, Dex and Dox, which is
reversible after withdrawal of ligands. In our previous work we
have shown that immunophenotype of conditionally immortalized
MSCs is not changed after prolonged culturing and upon
induction/deinduction [32]. These observations motivated us to
perform an extensive characterization of the expression of surface
antigens in conditionally immortalized BM MSCs. Here we report
the results on BM MSC immunophenotyping using 176 antibod-
ies, and to our knowledge this is the most comprehensive study of
surface markers expressed in mouse bone marrow MSCs to date
(Fig. 1, Table 1, Fig. S1, S2). Among 33 antigens that we detected
in conditionally immortalized MSCs, 13 markers have not been
previously characterized in mouse BM MSCs. Additionally, 3
markers (CD138, Cr1l, Sdc4) have not been reported for BM
MSCs neither from mice nor from other species.
Conditionally immortalized BM MSCs have practically indef-
inite proliferative potential, which allowed us establishing clonally
derived subpopulations. We found progenitors with distinct
differentiation potential among BM MSC subpopulations (Fig. 2),
which confirms heterogeneity of MSCs reported by others
[38,40,41,42]. By comparing immunophenotypes of clonally
derived progenitors we showed that osteogenic cells (with OA
and O properties) expressed higher level of CD200 (OX2) and
lower levels of SSEA4 and CD140a (PDGFRa) than non-
osteogenic (A clones). Our sorting experiments confirmed that
expression of those markers is distinctive for subpopulations with
different efficiencies of osteogenesis and adipogenesis (Fig. 3).
We showed that high expression of CD200 marks the
progenitors with higher potential for osteogenesis in expense of
adipogenic capacity. Our observations are in a good agreement
with the molecular function of CD200, which is to mediate
osteoblast-osteoclast interaction and to take part in regulation of
balance between bone formation and resorption [43,44]. Lee et al.
[43] reported that CD200 enhanced differentiation of primary
calvarial osteoblasts upon overexpression or after adding a soluble
form of CD200 to the cells. Our experiments showed that CD200
was upregulated during osteogenesis in BM MSCs, which may
indicate positive autoregulation during differentiation. Another
study suggested CD200 as a marker for multipotent human BM
MSCs characteristic for undifferentiated cells [25]. The authors
described a reduction in CD200 level after osteogenic and
adipogenic differentiation of BM MSCs, which contradicts to
our data and observations of the others [43]. We cannot explain
this discrepancy, however the difference in the role of CD200 in
human and mouse MSCs cannot be completely excluded.
We found that SSEA4 was characteristic for the cells with
higher adipogenic potential and lower osteogenic potential, which
was the opposite distribution to CD200 within BM MSC
populaiton. Detection of SSEA4 in our study is remarkable since
this molecule represents a globo-series glycosphingolipid and
would not be detected by transcriptomic or proteomic methods
[45]. Expression of SSEA4 in human and mouse BM MSCs was
previously described [46], and it was shown as heterogeneous in
expanded primary BM MSCs. SSEA4 positive cells were found to
be tripotential (osteo-, adipo-, chondrogenic), although with a low
mineralization efficiency, but unfortunately, a side by side
comparison with SSEA4 low expressing cells hasn’t been done.
We identified CD140a to be higher expressed in adipogenic
monopotential progenitors than in osteogenic, and further
confirmed higher adipogenic efficiency of CD140ahigh subpopu-
lation, but osteogenic property of CD140ahigh and CD140alow cells
was variable. Therefore, CD140a expression level did not
correlate with the capacity for the alternative differentiation
pathway, in contrast to the other markers analyzed in our work.
Indeed, we observed that CD140a was expressed among MSCs
independently of SSEA4 level (Fig. S4). CD140a was used for
prospective isolation of MSCs from mouse bone marrow [15]. In
this work, CD45negTER119neg cells from bone marrow were
separated into subpopulations with different expression of
PDGFRa and Sca1 and checked for differentiation potential.
Interestingly, only PDGFRapos cells exhibited adipogenic potential
(both Sca1pos and Sca1neg). This observation supports our data
obtained using in vitro cultured cells. Additionally, we found that
CD140a reached high level on the early stage of adipogenesis, also
in the OA clones that had initially a low level of CD140a, and then
dropped. Similar to this result, during adipogenic differentiation of
mouse embryonic stem (ES) cells PDGFRa expressing cells were
giving rise to adipocytes, but not PDGFRaneg [47]. It was also
shown that adding PDGF inhibited differentiation of pre-
adipocytes 3T3-L1 [48] and blocking of PDGF receptor by
antibodies promoted adipogenesis in MSCs [49]. Taking together
these data and our results, we suggest that high level of PDGFRa
marks adipogenic precursors at the early stage of commitment, but
has to be downregulated to proceed to terminally differentiated
state.
In conclusion, we performed a comprehensive characterization
of surface marker expression in mouse bone marrow MSCs and
their subsets using conditionally immortalized cells. Moreover, we
were able to identify the markers differentially expressed in the
distinct types of BM MSC progenitors, CD200 in osteogenic and
Figure 3. Cellular sorting of bone marrow MSC subsets with different levels of CD200, SSEA4 and CD140a expression. (A) FACS gates
for sorting of MSC subpopulations for high and low expression of CD200, SSEA4 and CD140a. (B) Quantitative RT-PCR for expression of markers used
for sorting, CD200 and CD140a (green color), and lineage-specific markers (osteogenic in blue and adipogenic in red), in the cells directly after sorting.
(C) The sorted subpopulations were differentiated into osteocytes (stained with Alizarin Red, 46) and adipocytes (stained with Oil Red, 206, percent
of adipocytes is indicated). (D) Comparison of osteogenic and adipogenic potentials in the sorted MSC subpopulations. Efficiency of osteogenic
differentiation was quantified by Alizarin Red extraction and measurement of OD at 490 nm of the eluate, and adipogenic differentiation was
assessed by adipocyte counting. High- and low-expressing markers subsets were compared and the percent of differentiation efficiency from the
maximal among them is shown. (E) Flow cytometry results of MSC subpopulations for the markers, which were used for sorting. After at least 5
passages in culture the positively sorted cells (red line) maintained elevated level of expression compared to the negatively sorted cells (blue line).
doi:10.1371/journal.pone.0051221.g003
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Figure 4. Expression of CD200, SSEA4 and CD140a during MSC differentiation. (A) Clonally derived conditionally immortalized MSCs were
differentiated into osteocytes (upper panel, Alizarin Red staining) or adipocytes (lower panel, Oil Red staining). Undifferentiated state, early time point
and late differentiation were analyzed (0, 3, 10 days of osteogenic induction, and 0, 3, 5 days of adipogenic induction). (B) Flow cytometry results of
the expression of CD200, SSEA4 and CD140a in the representative OA clone during differentiation time course (0, 3, 10 days of osteogenic treatment
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SSEA4 and CD140a in adipogenic cells. Our results conform to
the data obtained using primary cells and mice [15,43,47], and
provide an important insight to the identity of BM MSCs and
cellular composition of this cell population. We believe that our
findings would be effective for the studies of bone marrow stroma
functions and understanding biology of mesenchymal progenitor
cells: further investigations are anticipated.
Supporting Information
Figure S1 Expression of surface markers in condition-
ally immortalized mouse BM MSCs. Expression of 176
markers was checked by staining with antibodies and flow
cytometry of two MSC lines after de-induction of immortalization.
The results for 13 highly and 20 moderately/heterogeneously
expressed antigens are shown as histograms and percents of cells in
the positive gate are indicated (for one of the lines). Line – IgG
control, colored histogram – antibody staining.
(TIF)
Figure S2 The complete results of surface markers
screening in conditionally immortalized mouse BM
MSCs. Three 96-well plates containing antibodies, which were
used for the staining, are depicted (the empty wells contained
isotype controls or nothing). The color indicates the result of the
measurement as shown; the average percentage of cells in the
positive gate was calculated from the screening of two individual
lines.
(TIF)
Figure S3 Expression of surface markers in the BM
MSC subsets sorted for CD200, SSEA4 and CD140a. The
subpopulations of BM MSCs were sorted from two individual
conditionally immortalized lines for high and low expression of the
markers above, passaged for at least 5 times and each of them was
checked for the levels of all those three markers by flow cytometry.
The Whisker box plots show the ratio of the Mean Fluorescence
Intensity (MFI) in the population sorted for high level to MFI in
the one sorted for low expression of (A) CD200, (B) SSEA4 and (C)
CD140a. The dashed line represents ratio = 1, i. e. equal
expression. The results are summarized from two independent
measurements of subsets sorted from two lines. Statistical
significance was calculated using Student’s t-test. The cells sorted
for high expression of CD200, SSEA4, CD140a maintained
increased level of those markers as compared to the cells sorted for
low expression. Additionally, CD200high subpopulation exhibited
lower level of SSEA4 compared to CD200low, whilst SSEA4high
had decreased CD200 expression relatively to SSEA4low.
(TIF)
Figure S4 Co-expression of markers CD200 and SSEA4
or CD140a and SSEA4 in conditionally immortalized BM
MSCs. Conditionally immortalized BM MSCs were stained with
combinations of antibodies for CD200 and SSEA4 (upper panel)
or CD140a and SSEA4 (lower panel). The gating has been done
according to unstained control and stainings with individual
antibodies combined with all secondary reagents to exclude
unspecific staining. BM MSCs were mostly composed of the
subpopulations with CD200high SSEA4low and CD200low SSEA4-
high immunophenotypes and high expression of both markers was
exclusive. Expression of CD140a was detected within SSEA4high
and SSEA4low subsets. A percentage and Mean Fluorescence
Intensity for PE and APC staining are shown for the described
subpopulations.
(TIF)
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